Sector Gamma AS Has $4.84 Million Stock Position in Ascendis Pharma A/S $ASND

Sector Gamma AS boosted its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 43.1% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 24,327 shares of the biotechnology company’s stock after buying an additional 7,327 shares during the period. Sector Gamma AS’s holdings in Ascendis Pharma A/S were worth $4,836,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. First Horizon Advisors Inc. purchased a new position in shares of Ascendis Pharma A/S in the second quarter worth approximately $41,000. Hantz Financial Services Inc. grew its position in Ascendis Pharma A/S by 291.1% during the 2nd quarter. Hantz Financial Services Inc. now owns 352 shares of the biotechnology company’s stock worth $61,000 after purchasing an additional 262 shares in the last quarter. Farther Finance Advisors LLC raised its stake in Ascendis Pharma A/S by 115.3% during the 3rd quarter. Farther Finance Advisors LLC now owns 478 shares of the biotechnology company’s stock valued at $95,000 after purchasing an additional 256 shares during the period. Toth Financial Advisory Corp lifted its holdings in shares of Ascendis Pharma A/S by 33.7% in the third quarter. Toth Financial Advisory Corp now owns 595 shares of the biotechnology company’s stock valued at $118,000 after purchasing an additional 150 shares in the last quarter. Finally, GAMMA Investing LLC lifted its holdings in shares of Ascendis Pharma A/S by 15.2% in the third quarter. GAMMA Investing LLC now owns 735 shares of the biotechnology company’s stock valued at $146,000 after purchasing an additional 97 shares in the last quarter.

Analyst Upgrades and Downgrades

ASND has been the topic of several recent analyst reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Ascendis Pharma A/S in a research report on Wednesday, November 26th. Wall Street Zen downgraded Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a report on Saturday, November 15th. JPMorgan Chase & Co. lifted their price target on Ascendis Pharma A/S from $260.00 to $264.00 and gave the company an “overweight” rating in a report on Thursday, October 9th. Wolfe Research initiated coverage on shares of Ascendis Pharma A/S in a research note on Tuesday, November 18th. They issued a “peer perform” rating and a $255.00 target price for the company. Finally, Wedbush reissued an “outperform” rating and issued a $220.00 target price on shares of Ascendis Pharma A/S in a research report on Tuesday, November 18th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $264.44.

Ascendis Pharma A/S Stock Performance

ASND opened at $235.39 on Friday. The business has a 50 day moving average price of $210.60 and a 200 day moving average price of $199.63. Ascendis Pharma A/S has a twelve month low of $118.03 and a twelve month high of $238.84. The firm has a market cap of $14.59 billion, a P/E ratio of -53.02, a price-to-earnings-growth ratio of 1.24 and a beta of 0.46.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings results on Thursday, November 13th. The biotechnology company reported ($1.17) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.76). The business had revenue of $250.71 million during the quarter, compared to the consensus estimate of $246.91 million. As a group, analysts anticipate that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a Denmark?based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long?acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once?weekly growth hormone therapy approved by the U.S.